Pfizer Inc. today said during its quarterly earnings call that it will file by the end of May for full Food and Drug Administration approval for its COVID-19 vaccine. More than 131 million doses of the Pfizer vaccine have been administered in the U.S. since it was authorized for emergency use in December. In seeking full authorization for adults ages 16 to 85, Pfizer is moving toward directly marketing the shot to consumers. Pfizer also indicated that it will seek FDA’s approval to change the agency’s existing storage guidance, enabling the vaccine to be kept at standard refrigerated temperatures for up to four weeks. The drug maker also expects a FDA decision soon on its application for the vaccine’s emergency use in adolescents aged 12 to 15.

Related News Articles

Headline
The Food and Drug Administration yesterday approved using Olumiant (baricitinib) to treat COVID-19 in hospitalized adults requiring supplemental oxygen,…
Headline
The Food and Drug Administration last week extended to 24 months the shelf life for certain lots of refrigerated bamlanivimab. The combination monoclonal…
Headline
The Centers for Medicare & Medicaid Services Friday released updated guidance on COVID-19 vaccination coverage and reimbursement to help Medicaid, Children…
Headline
The Food and Drug Administration yesterday revised its emergency use authorization for the Johnson & Johnson COVID-19 vaccine to limit its use to…
Headline
COVID-19 vaccinations prevented an estimated 107,000 Medicare hospitalizations between January and May 2021, resulting in $2.6 billion in savings for Medicare…
Headline
Moderna today asked the Food and Drug Administration to authorize for emergency use its COVID-19 vaccine in children aged 6 months through 5 years, citing…